1. 厚生労働省. がん対策推進基本計画（第 3 期）＜平成 30 年 3 月 9 日閣議決定＞. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000183313.html [2022 年 8 月 30日閲覧]
2. 国立研究開発法人国立がん研究センター. がん情報サービス. https://ganjoho.jp/public/index.html [2022 年 8 月 30 日閲覧]
3. World Health Organization. THE GLOBAL HEALTH OBSERVATORY - Indicator Metadata Registry List.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3199 [2022 年8 月 30 日閲覧]
4. Sobota A, Ozakinci G. Fertility and parenthood issues in young female cancer patients—a systematic review. Journal of Cancer Survivorship. 2014;8(4):707-721.
5. Benedict C, Shuk E, Ford JS. Fertility Issues in Adolescent and Young Adult Cancer Survivors. Journal of Adolescent and Young Adult Oncology. 2016;5(1):48-57.
6. 厚生労働省. 令和３年度 出生に関する統計の概況.https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/tokusyu/syussyo07/index.html [2022 年 8 月 30 日閲覧]
7. Meirow D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy andradiation on female reproduction. Clinical Obstetrics and Gynecology. 2010;53(4):727-739.
8. Ben-Aharon I, Shalgi R. What lies behind chemotherapy-induced ovarian toxicity?Reproduction. 2012;144(2):153-163.
9. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncologyrecommendations on fertility preservation in cancer patients. Journal of Clinical Oncology. 2006;24(18):2917-2931.
10. 日本産科婦人科学会, 日本産婦人科医会. 産婦人科診療ガイドライン―産科編 2020.
11. 日本乳癌学会. 乳癌診療ガイドライン 2018 年版〔追補 2019〕. 金原出版.
12. 日本がん・生殖医療学会. 乳癌患者の妊娠・出産と生殖医療に関する診療ガイドライン2021 年版. 金原出版.
13. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. The Lancet Oncology. 2004;5(5):283-291.
14. Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Annals of Oncology. 2012;23(12):3016-3023.
15. Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study. The Lancet Oncology. 2012;13(9):887-896.
16. Lu D, Ludvigsson JF, Smedby KE, et al. Maternal Cancer During Pregnancy and Risks of Stillbirth and Infant Mortality. Journal of Clinical Oncology. 2017;35(14):1522-1529.
17. Momen NC, Arendt LH, Ernst A, et al. Pregnancy-associated cancers and birth outcomes in children: a Danish and Swedish population-based register study. BMJ Open. 2018;8(12):e022946.
18. de Haan J, Verheecke M, Van Calsteren K, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. The Lancet Oncology. 2018;19(3):337-346.
19. Danet C, Araujo M, Bos-Thompson MA, et al. Pregnancy outcomes in womenexposed to cancer chemotherapy. Pharmacoepidemiolo gy and Drug Safety. 2018;27(12):1302-1308.
20. Hiramatsu K, Barrett A, Miyata Y, on behalf of PhRMA Japan Medical Affairs Committee Working Group 1. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan. Drugs - Real World Outcomes. 2021;8(4):459-480.
21. Togo K, Yonemoto N. Real world data and data science in medical research: present and future. Japanese Journal of Statistics and Data Science. 2022.
22. JMDC Inc. Website. https://www.jmdc.co.jp/en/ [2022 年 8 月 30 日閲覧]
23. 日本薬剤疫学会. 日本における臨床疫学・薬剤疫学に応用可能なデータベース調査. https://www.jspe.jp/committee/020/0210/ [2022 年 8 月 30 日閲覧]
24. 独立行政法人医薬品医療機器総合機構. 製造販売後データベース調査で用いるアウトカム定義のバリデーション実施に関する基本的考え方（2020 年 7 月 31 日）. https://www.pmda.go.jp/files/000235927.pdf [2022 年 8 月 30 日閲覧]
25. U.S. Food and Drug Administration. Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products (Draft Guidance for Industry). 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-w orld-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory [2022 年 8 月 30 日閲覧]
26. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP).Module VIII – Post-authorisation safety studies (Rev 3). 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-phar macovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf [2022 年 8 月 30 日閲覧]
27. Andrade SE, Shinde M, Moore Simas TA, et al. Validation of an ICD-10-based algorithm to identify stillbirth in the Sentinel System. Pharmacoepidemiology and Drug Safety. 2021;30(9):1175-1183.
28. Hornbrook MC, Whitlock EP, Berg CJ, et al. Development of an algorithm to identify pregnancy episodes in an integrated health care delivery system. Health Services Research. 2007;42(2):908-927.
29. Lohse SR, Farkas DK, Lohse N, et al. Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients. Clinical Epidemiology. 2010;2:247-250.
30. Likis FE, Sathe NA, Carnahan R, McPheeters ML. A systematic review of validated methods to capture stillbirth and spontaneous abortion using administrative or claims data. Vaccine. 2013;31 Suppl 10:K74-82.
31. Wentzell N, Schink T, Haug U, Ulrich S, Niemeyer M, Mikolajczyk R. Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data. Pharmacoepidemiology and Drug Safety. 2018;27(9):1005-1010.
32. Naleway AL, Gold R, Kurosky S, et al. Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. Vaccine. 2013;31(27):2898-2903.
33. Matcho A, Ryan P, Fife D, Gifkins D, Knoll C, Friedman A. Inferring pregnancy episodes and outcomes within a network of observational databases. PLoS One. 2018;13(2):e0192033.
34. Tawfik DS, Gould JB, Profit J. Perinatal Risk Factors and Outcome Coding in Clinical and Administrative Databases. Pediatrics. 2019;143(2).
35. Ishikawa T, Obara T, Nishigori H, et al. Development of algorithms to determine the onset of pregnancy and delivery date using health care administrative data in a university hospital in Japan. Pharmacoepidemiology and Drug Safety. 2018;27(7):751-762.
36. Ishikawa T, Oyanagi G, Obara T, et al. Validity of congenital malformation diagnoses in healthcare claims from a university hospital in Japan. Pharmacoepidemiology and Drug Safety. 2021.
37. 日本癌治療学会. 小児、思春期・若年がん患者の妊孕性温存に関する診療ガイドライン2017 年版. 金原出版
38. Coccia PF. Overview of Adolescent and Young Adult Oncology. Journal of Oncology Practice. 2019;15(5):235-237.
39. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines inOncology. Adolescent and Young Adult (AYA) Oncology version 2. 2022. https://www.nccn.org/professionals/physician_gls/pdf/aya.pdf [2022 年 8 月 30 日閲覧]
40. Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM. Association between delayedinitiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13:240.
41. Raphael MJ, Biagi JJ, Kong W, Mates M, Booth CM, Mackillop WJ. The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment. 2016;160(1):17-28.
42. Gagliato DM, Lei X, Giordano SH, et al. Impact of delayed neoadjuvant systemic chemotherapy on overall survival among breast cancer patients. The Oncologist. 2020.
43. 日本乳癌学会. 乳癌診療ガイドライン治療編 2018 年版 第 4 版. 金原出版.
44. Sato I, Yagata H, Ohashi Y. The accuracy of Japanese claims data in identifying breast cancer cases. Biological and Pharmaceutical Bulletin. 2015;38(1):53-57.
45. Peto R, Davies C, Godwin J, et al. Comparisons between differentpolychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. The Lancet. 2012;379(9814):432-444.
46. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. The New England Journal of Medicine. 2005;352(22):2302-2313.
47. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Journal of Clinical Oncology. 2009;27(8):1177-1183.
48. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. Journal of Clinical Oncology. 2008;26(1):44-53.
49. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. The Cochrane Database of Systematic Reviews. 2012;2012(4):Cd006243.
50. Debono DJ, Kohnke JM, Helft PR. Addressing Fertility in Patients With Advanced Cancer: How the Quality Oncology Practice Initiative Standards and ASCO Guidelines Facilitate Ethical Communication. Journal of Oncology Practice. 2009;5(6):298-300.
51. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients withcancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2013;31(19):2500-2510.
52. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 2018;36(19):1994-2001.
53. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116(4):791-798.
54. Ganz PA, Land SR, Geyer CE, Jr., et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. Journal of Clinical Oncology. 2011;29(9):1110-1116.
55. Lambertini M, Campbell C, Bines J, et al. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. Journal of the National Cancer Institute. 2019;111(1):86-94.
56. Pondé NF, Zardavas D, Piccart M. Progress in adjuvant systemic therapy for breast cancer. Nature Reviews Clinical Oncology. 2019;16(1):27-44.
57. Tal R, Seifer DB. Ovarian reserve testing: a user's guide. American Journal of Obstetrics and Gynecology. 2017;217(2):129-140.
58. Shimizu C, Bando H, Kato T, Mizota Y, Yamamoto S, Fujiwara Y. Physicians'knowledge, attitude, and behavior regarding fertility issues for young breast cancer patients: a national survey for breast care specialists. Breast cancer. 2013;20(3):230-240.
59. Furui T, Takai Y, Kimura F, et al. Fertility preservation in adolescent and youngadult cancer patients: From a part of a national survey on oncofertility in Japan. Reproductive Medicine and Biology. 2019;18(1):97-104.
60. Duffy CM, Allen SM, Clark MA. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. Journal of Clinical Oncology. 2005;23(4):766-773.
61. Niemasik EE, Letourneau J, Dohan D, et al. Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. Journal of cancer survivorship : research and practice. 2012;6(3):324-332.
62. Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. Journal of Clinical Oncology. 2014;32(11):1151-1156.
63. Chubak J, Pocobelli G, Weiss NS. Tradeoffs between accuracy measures for electronic health care data algorithms. Journal of Clinical Epidemiology. 2012;65(3):343-349.e342.
64. 厚生労働省. 不妊治療に関する取組.https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kodomo/kodomo_kosodate/boshi- hoken/funin-01.html [2022 年 8 月 30 日閲覧]
65. Albright CM, Wenstrom KD. Malignancies in pregnancy. Best Practice & ResearchClinical Obstetrics & Gynaecology. 2016;33:2-18.
66. Ngu SF, Ngan HY. Chemotherapy in pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology. 2016;33:86-101.
67. Williams TJ, Turnbull KE. CARCINOMA IN SITU AND PREGNANCY. Obstetrics & Gynecology. 1964;24:857-64.
68. Anderson C, Engel SM, Mersereau JE, et al. Birth Outcomes Among Adolescent and Young Adult Cancer Survivors. JAMA oncology. 2017;3(8):1078-1084.
69. Kao WH, Kuo CF, Chiou MJ, et al. Adverse birth outcomes in adolescent and young adult female cancer survivors: a nationwide population-based study. British journal of Cancer. 2020.
70. World Health Organization. Fact sheets - Preterm birth (19 February 2018).https://www.who.int/news-room/fact-sheets/detail/preterm-birth [2022 年 8 月 30 日閲覧]
71. 日本薬剤疫学会.「日本における傷病名を中心とするレセプト情報から得られる指標のバリデーションに関するタスクフォース」報告書. https://www.jspe.jp/committee/030/0271_1/ [2022 年 8 月 30 日閲覧]
72. Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. The Annals of Pharmacotherapy. 2001;35(11):1485-1489.
73. 厚生労働省. 妊産婦に対する保健・医療体制の在り方に関する検討会.https://www.mhlw.go.jp/stf/shingi/other-hoken_553056_00007.html [2022 年 8 月 30日閲覧]
74. Reports of CIOMS Working Group VI: Management of Safety. Information from Clinical Trials. Appendix 7. The council for International Organization of Medical Sciences. 2005; 276-278.https://cioms.ch/wp-content/uploads/2017/01/Mgment_Safety_Info.pdf [2022 年 8 月30 日閲覧]
75. Sekine M, Kobayashi Y, Tabata T, et al. Malignancy during pregnancy in Japan: an exceptional opportunity for early diagnosis. BMC Pregnancy and Childbirth. 2018;18(1):50.
76. Kobayashi Y, Tabata T, Omori M, et al. A Japanese survey of malignant disease in pregnancy. International Journal of Clinical Oncology. 2019;24(3):328-333.
77. Peccatori FA, Azim HA, Jr., Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24 Suppl 6:vi160-170.
78. Wolters V, Heimovaara J, Maggen C, et al. Management of pregnancy in women with cancer. International Journal of Gynecological Cancer. 2021;31(3):314-322.
79. National Comprehensive Cancer Network. NCCN Guidelines Breast CancerVersion 3. 2022.https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419 [2022 年 8 月30 日閲覧]
80. Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006;107(6):1219-1226.
81. Murthy RK, Theriault RL, Barnett CM, et al. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Research. 2014;16(6):500.
82. Varghese SS, Eekhoudt CR, Jassal DS. Mechanisms of anthracycline -mediated cardiotoxicity and preventative strategies in women with breast cancer. Molecular and Cellular Biochemistry. 2021;476(8):3099-3109.
83. 厚生労働省. 令和 2（2020）年医療施設（静態・動態）調査（確定数）・病院報告の概況. https://www.mhlw.go.jp/toukei/saikin/hw/iryosd/20/ [2022 年 8 月 30 日閲覧]
84. Carbonell Esteve JL, Varela L, Velazco A, Tanda R, Sánchez C. 25 mg or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion: a randomized trial. Gynecologic and Obstetric Investigation. 1999;47(3):182-187.
85. Kulier R, Kapp N, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. The Cochrane Database of Systematic Reviews. 2011;2011(11):Cd002855.
86. Kim JH, Kim HS, Sung CW, Kim KJ, Kim CH, Lee KY. Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy. Lung Cancer (Amsterdam, Netherlands). 2008;59(2):270-273.
87. Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Fetaloutcome after in utero exposure to cancer chemotherapy. Archives of Internal Medicine. 1992;152(3):573-576.
88. Pavlidis NA. Coexistence of pregnancy and malignancy. The Oncologist.2002;7(4):279-287.
89. Bando H, Kataoka A, Tamaki K, et al. Physician's knowledge, attitudes and practice pattern for breast cancer diagnosed during pregnancy: a survey among breast care specialists in Japan. Breast Cancer. 2020;27(5):796-802.
90. データサイエンスアドバイザリーグループ有志. 科学的な安全対策への転換をめざして（2）－個別の有害事象が副作用になるまで－. 医薬品医療機器レギュラトリーサイエンス. 2014;45(2):98-105
論文の公開元へ
